英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
provably查看　provably　在百度字典中的解释百度英翻中〔查看〕
provably查看　provably　在Google字典中的解释Google英翻中〔查看〕
provably查看　provably　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • FDA approves cemiplimab-rwlc for adjuvant treatment of . . .
    On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc ) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma
  • What Libtayo Means for High-Risk Cutaneous Squamous Cell . . .
    Key Takeaways Libtayo's FDA approval offers an effective adjuvant option for high-risk cutaneous squamous cell carcinoma, reducing recurrence risk by 68% in the C-POST trial Administered post-surgery and radiation, Libtayo prevents recurrence rather than treating existing tumors, with a safety profile consistent with advanced cancer use
  • LIBTAYO® (cemiplimab-rwlc) in Advanced NSCLC, BCC, CSCC . . .
    LIBTAYO is a prescription medication used to treat adults with a type of skin cancer called cutaneous squamous cell carcinoma (CSCC) that has spread or cannot be cured by surgery or radiation
  • Libtayo® (cemiplimab-rwlc) Approved in the U. S. as First and . . .
    Libtayo® (cemiplimab-rwlc) Approved in the U S as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
  • LIBTAYO® (cemiplimab-rwlc) for Treatment in Advanced CSCC
    LIBTAYO® (cemiplimab-rwlc) is indicated for patients with locally advanced or metastatic cutaneous squamous cell carcinoma (laCSCC or mCSCC) who are not candidates for curative surgery or curative radiation Review Important Safety Information and full Prescribing Information
  • Libtayo: Uses, Side Effects, Warnings - Drugs. com
    Libtayo (cemiplimab-rwlc) is used to treat metastatic cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer Includes Libtayo side effects, interactions and indications
  • FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment . . .
    FDA approved of Regeneron Pharmaceutical’s Libtayo (cemiplimab-rwlc)as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) who are at an increased risk of recurrence following surgery and radiation 1 Libtayo was reviewed by FDA under Priority Review, a method reserved for medicines representing a potential improvement in efficacy or safety in treatments of
  • Libtayo First PD-1 Inhibitor Treatment for Cutaneous Squamous . . .
    The U S Food and Drug Administration (FDA) approved Libtayo (cemiplimab, REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with locally advanced and unresectable CSCC, the second deadliest skin cancer after melanoma
  • Cemiplimab-rwlc (Libtayo) Updates 2025: Uses in cancer, Side . . .
    The ARCH trial (NCT06931717) is a multicentre, phase III study evaluating adjuvant Libtayo in patients with resected stage II–IIIA non-small cell lung cancer (NSCLC) who have not received prior chemotherapy Participants receive Libtayo intravenously on a scheduled regimen, with treatment continuing until relapse or toxicity
  • Cemiplimab Approved for Squamous Cell Skin Cancer - NCI
    The immunotherapy drug cemiplimab (Libtayo) has been approved by FDA for advanced cutaneous squamous cell carcinoma, a common type of skin cancer





中文字典-英文字典  2005-2009